Sigma Planning Corp Has $631,000 Stock Position in Liquidia Co. (NASDAQ:LQDA)

Sigma Planning Corp trimmed its position in Liquidia Co. (NASDAQ:LQDA) by 42.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 63,095 shares of the company’s stock after selling 46,315 shares during the quarter. Sigma Planning Corp owned approximately 0.08% of Liquidia worth $631,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Quest Partners LLC acquired a new position in shares of Liquidia in the second quarter worth about $27,000. Hilltop National Bank acquired a new stake in shares of Liquidia during the second quarter worth approximately $33,000. Deuterium Capital Management LLC acquired a new stake in shares of Liquidia during the second quarter worth approximately $120,000. Clear Harbor Asset Management LLC acquired a new stake in shares of Liquidia during the third quarter worth approximately $100,000. Finally, Signaturefd LLC boosted its holdings in shares of Liquidia by 38,400.0% during the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock worth $100,000 after purchasing an additional 9,984 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Rajeev Saggar sold 2,526 shares of Liquidia stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $11.19, for a total value of $28,265.94. Following the transaction, the insider now owns 204,857 shares of the company’s stock, valued at $2,292,349.83. This trade represents a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Russell Schundler sold 2,576 shares of Liquidia stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $28,619.36. Following the completion of the transaction, the general counsel now directly owns 486,048 shares in the company, valued at approximately $5,399,993.28. This represents a 0.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,551 shares of company stock valued at $236,021 over the last 90 days. 30.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of Liquidia in a report on Thursday. Raymond James upgraded shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. Scotiabank began coverage on shares of Liquidia in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price target for the company. Bank of America reduced their target price on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, August 20th. Finally, Lifesci Capital began coverage on shares of Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Liquidia Stock Down 2.4 %

NASDAQ:LQDA opened at $10.03 on Friday. Liquidia Co. has a 12 month low of $6.10 and a 12 month high of $16.99. The firm has a market cap of $769.86 million, a price-to-earnings ratio of -6.38 and a beta of 0.21. The company’s 50 day moving average is $10.48 and its 200-day moving average is $11.52.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).